Beyond Air Beheer
Beheer criteriumcontroles 3/4
Beyond Air's CEO is Steve Lisi, appointed in Jun 2017, has a tenure of 7.42 years. total yearly compensation is $1.73M, comprised of 37.5% salary and 62.5% bonuses, including company stock and options. directly owns 6.62% of the company’s shares, worth $1.53M. The average tenure of the management team and the board of directors is 2.3 years and 7 years respectively.
Belangrijke informatie
Steve Lisi
Algemeen directeur
US$1.7m
Totale compensatie
| Percentage CEO-salaris | 37.5% |
| Dienstverband CEO | 7.4yrs |
| Eigendom CEO | 6.6% |
| Management gemiddelde ambtstermijn | 2.3yrs |
| Gemiddelde ambtstermijn bestuur | 7yrs |
Recente managementupdates
Recent updates
We're Keeping An Eye On Beyond Air's (NASDAQ:XAIR) Cash Burn Rate
Apr 05
Will Beyond Air (NASDAQ:XAIR) Spend Its Cash Wisely?
Dec 14Beyond Air presents pilot at-home study data; stock earlier snaps 7-day losing streak
Oct 17Beyond Air: Bottom Line Fundamentals Keep Buyers At Bay
Sep 08Beyond Air affiliate Beyond Cancer doses patient in phase 1 study of ultra-high concentration nitric oxide therapy
Aug 23Beyond Air reaches six-month high after $2.3M insider transactions
Jul 06Companies Like Beyond Air (NASDAQ:XAIR) Are In A Position To Invest In Growth
May 02Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$58m |
| Mar 31 2024 | US$2m | US$650k | -US$60m |
| Dec 31 2023 | n/a | n/a | -US$67m |
| Sep 30 2023 | n/a | n/a | -US$63m |
| Jun 30 2023 | n/a | n/a | -US$59m |
| Mar 31 2023 | US$9m | US$650k | -US$56m |
| Dec 31 2022 | n/a | n/a | -US$56m |
| Sep 30 2022 | n/a | n/a | -US$51m |
| Jun 30 2022 | n/a | n/a | -US$47m |
| Mar 31 2022 | US$6m | US$450k | -US$43m |
| Dec 31 2021 | n/a | n/a | -US$28m |
| Sep 30 2021 | n/a | n/a | -US$26m |
| Jun 30 2021 | n/a | n/a | -US$23m |
| Mar 31 2021 | US$2m | US$450k | -US$23m |
| Dec 31 2020 | n/a | n/a | -US$23m |
| Sep 30 2020 | n/a | n/a | -US$22m |
| Jun 30 2020 | n/a | n/a | -US$21m |
| Mar 31 2020 | US$1m | US$450k | -US$20m |
| Dec 31 2019 | n/a | n/a | -US$15m |
| Sep 30 2019 | n/a | n/a | -US$13m |
| Jun 30 2019 | n/a | n/a | -US$11m |
| Mar 31 2019 | US$3m | US$450k | -US$7m |
| Dec 31 2018 | n/a | n/a | -US$5m |
| Sep 30 2018 | n/a | n/a | -US$5m |
| Jun 30 2018 | n/a | n/a | -US$10m |
| Mar 31 2018 | US$537k | US$130k | -US$11m |
| Dec 31 2017 | US$2m | US$163k | -US$18m |
Compensatie versus markt: Steve's total compensation ($USD1.73M) is above average for companies of similar size in the US market ($USD655.65K).
Compensatie versus inkomsten: Steve's compensation has been consistent with company performance over the past year.
CEO
Steve Lisi (53 yo)
7.4yrs
Tenure
US$1,733,000
Compensatie
Mr. Steven Adam Lisi, also known as Steve, has been the Chief Executive Officer of Beyond Air, Inc. (formerly known as AIT Therapeutics, Inc.) since June 14, 2017. Mr. Lisi serves as Chief Executive Office...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Chairman of the Board | 7.4yrs | US$1.73m | 6.62% $ 1.5m | |
| Chief Operating Officer | 2.3yrs | US$799.00k | 0.14% $ 31.9k | |
| Chief Executive Officer of NeuroNOS | less than a year | US$952.00k | 0% $ 0 | |
| CFO, Principal Financial Officer & Principal Accounting Officer | 3.2yrs | US$1.13m | 0.039% $ 9.1k | |
| Head of Investor Relations | no data | geen gegevens | geen gegevens | |
| Senior Medical Director Global Clinical Leadership & Member of Scientific Advisory Board | 2.9yrs | geen gegevens | geen gegevens | |
| Chief Commercial Officer | less than a year | geen gegevens | geen gegevens | |
| Head of Research & Clinical Development | less than a year | geen gegevens | geen gegevens | |
| Corporate Secretary | no data | US$643.57k | geen gegevens |
2.3yrs
Gemiddelde duur
54yo
Gemiddelde leeftijd
Ervaren management: XAIR's management team is considered experienced (2.3 years average tenure).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Chairman of the Board | 7.8yrs | US$1.73m | 6.62% $ 1.5m | |
| Senior Medical Director Global Clinical Leadership & Member of Scientific Advisory Board | 11.8yrs | geen gegevens | geen gegevens | |
| Independent Director | 6.8yrs | US$51.30k | 0.027% $ 6.2k | |
| Independent Director | 5.8yrs | US$102.60k | 9.65% $ 2.2m | |
| Independent Director | 7.8yrs | US$51.30k | 0.31% $ 70.9k | |
| Independent Director | 6.3yrs | US$51.30k | 0.031% $ 7.3k | |
| Member of Scientific Advisory Board | 6.8yrs | US$75.00k | geen gegevens | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 7.3yrs | US$51.30k | 0.092% $ 21.4k | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens |
7.0yrs
Gemiddelde duur
60yo
Gemiddelde leeftijd
Ervaren bestuur: XAIR's board of directors are considered experienced (7 years average tenure).